Salmon et al. recently demonstrated that systemic administration of Flt3L expanded and mobilized CD103+ DC progenitors from the bone marrow and led to the accumulation of immature CD103+ DC within tumor masses, and subsequent injection of polyI:C intratumorally induced local maturation of these cells and enhanced their ability to recruit and activate melanoma-specific effector CD8+ T cells, leading to tumor regression (47). Here, CD8A is linked to neoplasm.